Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Rhea-AI Summary

Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced an upcoming R&D Day event scheduled for June 26, 2025, from 9:00 AM to 12:00 PM ET in New York, with both in-person and virtual attendance options. The event will showcase updates on the company's early-stage pipeline assets, development strategies, and plans for long-term value creation. Key presentation topics will include their NDC platform with CRN09682 for NETs and beyond, TSH antagonist developments for Graves' disease and thyroid eye disease (TED), and SST3 agonist research for autosomal polycystic kidney disease (ADPKD). The event will conclude with a live Q&A session.

SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET.

The event will provide an update including data on Crinetics' early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value. Key topics will include:

• NETs and beyond – NDC platform with CRN09682
• Graves’ disease and thyroid eye disease (TED) - TSH antagonist
• Autosomal polycystic kidney disease (ADPKD) - SST3 agonist
  

A live question-and-answer session will follow the formal presentations. To register, click here.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

When is Crinetics Pharmaceuticals (CRNX) hosting its R&D Day in 2025?

Crinetics Pharmaceuticals will host its R&D Day on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET in New York.

What topics will be covered at the CRNX R&D Day 2025?

The R&D Day will cover updates on NETs and the NDC platform with CRN09682, TSH antagonist for Graves' disease and thyroid eye disease, and SST3 agonist for autosomal polycystic kidney disease (ADPKD).

Will Crinetics' R&D Day 2025 be available virtually?

Yes, Crinetics Pharmaceuticals is offering both in-person and virtual attendance options for their R&D Day event.

What pipeline updates will CRNX present at their R&D Day?

Crinetics will present updates on their early-stage pipeline assets, including their NDC platform, TSH antagonist developments, and SST3 agonist research, along with their portfolio strategy for long-term value creation.